Bright Minds Biosciences

About Bright Minds Biosciences

Bright Minds is a biotechnology company focused on developing innovative solutions for mental health and neurology. Their mission is to heal the central nervous system and brain through the regulation of serotonin, using a proprietary chemistry platform to create highly selective 5-HT2A and 5-HT2C agonists.

Products & Services

Pipeline:A range of drug development projects targeting mental health and neurological disorders.

Epilepsy Program (BMB-101):Focused on developing treatments for epilepsy and related disorders.

Neuropsychiatry Program:Aimed at addressing mental health issues through innovative drug therapies.

Pain Program:Dedicated to developing solutions for pain management.

Specialties

Neuroscience Mental Health Neurology Serotonin Regulation Drug Development Epilepsy Treatment Neuropsychiatry Psychedelic Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 175050000 MR: - FA: US$175,050,000 FAN: 175050000	D: 2026-01-09 FD: 2026-01-09	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 175050000 MR: - FA: $175,050,000 FAN: 175050000	D: 2026-01-07 FD: 2026-01-07	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: US$100 million FAN: 100000000	D: 2026-01-06 FD: 2026-01-06	4 investors
4	RT: At-the-Market Offering T: - FT: At-the-Market Offering	A: 100000000 MR: - FA: US$100 million FAN: 100000000	D: 2025-09-04 FD: 2025-09-04	2 investors
5	RT: Private Placement T: - FT: Private Placement	A: 35000000 MR: - FA: USD$35,000,000 FAN: 35000000	D: 2024-11-04 FD: 2024-11-04	8 investors
6	RT: Non-brokered Private Placement T: - FT: Non-brokered Private Placement	A: 35000000 MR: - FA: 35,000,000 FAN: 35000000	D: 2024-10-18 FD: 2024-10-18	-
7	RT: Non-brokered Private Placement T: - FT: Non-brokered Private Placement	A: 900000 MR: - FA: up to $900,000 FAN: 900000	D: 2023-12-06 FD: 2023-12-06	1 investors

Public Offering Latest

2026-01-09

$175.1M

4 investors (Pro only)

Public Offering 2026-01-07

$175.1M

Public Offering 2026-01-06

$100.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jan Torleif Pedersen

Innovative and highly experienced leader in drug discovery research

S

Stephen D. Collins

R&D Leader

T

Terence J. O'Brien

Chair of Medicine (Neurology) and Head, The School of Translational Medicine, Monash University

J

Joseph E. Sullivan, MD

Professor of Neurology and Pediatrics and Director of the UCSF Pediatric Epilepsy Center of Excellence

D

Dennis J. Dlugos, MD

Professor of Neurology and Pediatrics at the University of Pennsylvania and Director, Pediatric Epilepsy Program at Children's Hospital of Philadelphia

J

Jacqueline French

Professor of Neurology

View 39 more team members with Pro

Unlock Full Team Directory

Recent News